NASDAQ · SCYX
SCYNEXIS, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for SCYX: Nov 4, 2026
SCYNEXIS, Inc. Common Stock is estimated to report earnings on 11/04/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 1 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.4. The reported EPS for the same quarter last year was $-1.36.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.40 | $-0.40 | $-0.40 | 1 |
| Dec 2026 | $-0.24 | $-0.24 | $-0.24 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
RTTNews · Fintel- RTTNews · Oct 22, 9:56 AM EDTSCYNEXIS Secures Up To $214M In BARDA Support For SCY-247 Development; Stock Up(RTTNews) – SCYNEXIS (SCYX) announced positive topline results from its Phase 1 study evaluating the intravenous formulation of SCY-247, a second-generation triterpenoid antifungal candidate being developed for the treatment of invasive candidiasis and prevention of invasive fung
- RTTNews · Oct 22, 9:42 AM EDTSCYNEXIS: IV SCY-247 Shows Favorable Safety And Exposure In Phase 1 Study(RTTNews) – SCYNEXIS (SCYX) reported positive Phase 1 results for intravenous SCY-247, an antifungal candidate for invasive fungal infections.
- RTTNews · Oct 6, 8:15 AM EDTSCYNEXIS Reports Favorable Phase 1 Results For ADPKD Drug(RTTNews) – SCYNEXIS Inc. (SCYX) said it has completed a Phase 1 study of SCY-770, a novel oral, selective direct AMPK activator being developed for autosomal dominant polycystic kidney disease (ADPKD).
- RTTNews · Sep 10, 8:17 AM EDTScynexis Names Sanjay Subramanian CFO(RTTNews) – Scynexis Inc. (SCYX), a clinical-stage biotechnology company focused on severe rare diseases, on Thursday appointed Sanjay Subramanian as Chief Financial Officer, effective September 9.
- RTTNews · Aug 11, 1:00 AM EDTSCYNEXIS Swings To Q2 Profit; Expects Phase 1 Topline Data For SCY-770 In Q3 2026;Stock Up(RTTNews) – SCYNEXIS, Inc. (SCYX), a clinical-stage biotechnology company, reported financial results for the second quarter ended June 30, 2026, swinging to a net profit compared to a loss last year. In addition, the company provided an update on its investigational pipeline.
- Fintel · May 14, 7:26 AM EDTSCYNEXIS (SCYX) Price Target Increased by 20.73% to 4.28The average one-year price target for SCYNEXIS (NasdaqCM:SCYX) has been revised to $4.28 / share. This is an increase of 20.73% from the prior estimate of $3.54 dated April 25, 2026. The price target is an average of many targets provided by analysts. The late
- RTTNews · May 12, 6:49 AM EDTSCYNEXIS Reports Wider Q1 Loss, Advances Pipeline Programs; Stock Down(RTTNews) – SCYNEXIS, Inc. (SCYX), a clinical-stage biotechnology company focused on severe rare diseases, reported first-quarter 2026 financial results and highlighted progress across its pipeline including AMPK activator SCY-770 and antifungal candidates SCY-247.
- RTTNews · Mar 31, 7:42 AM EDTPoxel To Sell PXL770 To Scynexis For Up To $196 Mln; Shares Up(RTTNews) – Poxel SA (POXEL.PA, PXXLF), a clinical-stage biopharmaceutical company, on Tuesday announced that it has agreed to sell its drug candidate PXL770 to Scynexis, Inc. (SCYX), for up to $196 million.
- RTTNews · Mar 5, 9:53 AM ESTScynexis FY25 Loss Narrows; Plans SCY-247 Expanded Access Program In H1(RTTNews) – Scynexis Inc. (SCYX), a biotechnology company, reported a narrower loss for the full year 2025, backed by improved revenue, compared to the prior year
- RTTNews · Mar 4, 7:32 PM ESTSCYNEXIS Posts Narrower FY25 Loss, Advances Next-Gen Antifungal Pipeline(RTTNews) – SCYNEXIS, Inc. (SCYX) has reported its full-year 2025 results, while highlighting progress across its antifungal pipeline, including its next-generation candidate SCY-247 and updates on its partnership with GSK for BREXAFEMME.
- RTTNews · Feb 26, 10:36 AM ESTSCYNEXIS Doses First Participants In Phase 1 Study Of Intravenous Antifungal SCY-247(RTTNews) – SCYNEXIS Inc.'s (SCYX) Phase 1 single ascending dose and multiple ascending dose trial of intravenous SCY-247 has dosed the first participants.
- RTTNews · Jan 21, 11:16 AM ESTSCYNEXIS Gets FDA QIDP And Fast Track Designations For SCY-247(RTTNews) – SCYNEXIS, Inc. (SCYX) announced that the U.S. FDA has granted Qualified Infectious Disease Product (QIDP) and Fast Track designations for SCY-247.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for SCYNEXIS, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.